August 2020

Aurobindo Pharma’s JV, Eugia Pharma receives FDA approval for Tamoxifen Citrate Tablets USP, 10 mg and 20 mg

East Windsor, N.J. – Aurobindo Pharma’s JV, Eugia Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tamoxifen Citrate Tablets USP, 10 mg and 20 mg. Aurobindo’s  JV, Eugia Pharma Tamoxifen Citrate Tablets USP, 10 mg and 20 mg. are an AB-rated generic equivalent to the reference listed drug (RLD), Nolvadex® Tablets, […]

Aurobindo Pharma’s JV, Eugia Pharma receives FDA approval for Tamoxifen Citrate Tablets USP, 10 mg and 20 mg Read More »

Aurobindo Receives FDA Approval for Methocarbamol Tablets USP, 750 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Methocarbamol Tablets USP, 750 mg. Aurobindo’s Methocarbamol Tablets USP, 750 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Robaxin-750® Tablets of Auxilium Pharmaceuticals, LLC. Methocarbamol Tablets are indicated for: Indicated as an adjunct

Aurobindo Receives FDA Approval for Methocarbamol Tablets USP, 750 mg Read More »

Aurobindo received FDA Approval for Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg.  Aurobindo’s Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg, are an AB-rated generic equivalent to the reference listed drug (RLD), ProAmatine Tablets

Aurobindo received FDA Approval for Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg Read More »